Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates By Earnings Published 03/05/2026, 07:24 PM Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates 0 LCTX -5.64% Investing.com - Lineage Cell Therapeutics (NYSE: LCTX ) reported first quarter EPS of $0.004, $0.05 better than the analyst estimate of $-0.046. Revenue for the quarter came in at $6.6M versus the consensus estimate of $1.96M. Lineage Cell Therapeutics’s stock price closed at $1.84. It is up 6.980% in the last 3 months and up 250.280% in the last 12 months. Lineage Cell Therapeutics saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Lineage Cell Therapeutics’s stock price’s past reactions to earnings here . According to InvestingPro , Lineage Cell Therapeutics’s Financial Health score is " fair performance ". Check out Lineage Cell Therapeutics’s recent earnings performance , and Lineage Cell Therapeutics’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Read full article at source